Introduction {#sec1}
============

Despite the development of imaging techniques, controversy concerning how to determine the diagnostic algorithm in patients with hyperparathyroidism still remains. Due to their small size and varying location, normal parathyroid glands are not visible in any of the imaging techniques; it is possible to visualize parathyroids only when they are enlarged and/or hyperfunctioning.

The decision whether imaging will bring any benefit to the patients affects nearly every step of the diagnostic process: patient selection, type of imaging techniques to be used as well as interpretation of results^([@cit0001]--[@cit0004])^. In many cases, an imaging examination before the first surgery is not needed. Only in cases of hyperthyroidism recurrence or unsuccessful operations does the visualization of the parathyroid glands become necessary. However since in the recent years minimally invasive parathyroidectomy has become the treatment of choice, it is believed that the majority of surgeons prefer to have a localization study conducted before operation^([@cit0005])^.

Diagnostic imaging techniques routinely used include ultrasound (US), scintigraphy (SC), computed tomography (CT) and magnetic resonance imaging (MRI). The most commonly used techniques are US and SC^([@cit0006]--[@cit0008])^. In the literature, the authors are unanimous in the opinion that the sensitivity and specificity of scintigraphy are superior to other imaging techniques. They also agree that ultrasonography is the most available. However, an algorithm for using different imaging methods as well as their sensitivity and specificity vary depending on the population of patients, experience of physicians and protocols used. The aim of the present research was to determine the usefulness of parathyroid scintigraphy and ultrasonography in patients diagnosed for hyperparathyroidism in own material.

Material and method {#sec2}
===================

The results of US and SC examinations in 96 operated patients with clinically and biochemically documented primary (70), secondary (15), tertiary (5) hyperparathyroidism and MEN1 syndrome (6) were retrospectively analyzed. Patients gave their informed consent to the study. Radioisotope studies were performed in the Department of Nuclear Medicine, SP CSK, Medical University in Warsaw. The diagnosis of hyperparathyroidism was determined based on serum calcium, phosphate and parathyroid hormone levels. The clinical characteristics are listed in the [Tab. 1](#t0001){ref-type="table"}.

###### 

Clinical characteristics of the patients

  --------------------------------------------------- ------------------------------- ---- --------
  **Age (years)**                                     48.8 (17-79); *SD* 15.07             
  **Female pts (%)**                                  81/96 (84.4%)                        
  **Primary hyperparathyroidism**                     76 (79.2%)                           
  **Secondary hyperparathyroidism**                   15 (15.63%)                          
  **Tertiary hyperparathyroidism**                    5 (5.21%)                            
  **Persistent/recurrent hyperparathyroidism**        26 (27.1%)                           
  **Serum PTH (pg/ml)**                               718.7 (60.7-3000); *SD* 792.3        
  **Serum Ca (mmol/l)**                               3.06 (2.14-6.2); *SD* 0.55           
  **Serum PO4 (mg/dl)**                               1.26 (0.5-3.2); *SD* 0.75            
  **Nodular goiter**                                  41                              --   42.70%
  **Nephrolithiasis**                                 22                              --   22.90%
  **Osteporosis complicated with fracture**           9                               --   9.40%
  **Peptic ulcer disease**                            4                               --   4.20%
  **Hashimoto disease**                               3                               --   3.10%
  **Osteitis fibrosa**                                2                               --   2.10%
  **Renal insufficiency treated with hemodialysis**   15                              --   15.60%
  **Cholelithiasis**                                  1                               --   1.04%
  **Renal transplant**                                5                               --   5.20%
  --------------------------------------------------- ------------------------------- ---- --------

The patients were clinically evaluated, which included taking medical history, physical examination, laboratory tests, neck ultrasonography and scintigraphy of the neck and upper mediastinum.

Scintigraphy {#sec2.1}
------------

All patients underwent a ^99m^Tc hexakis-2-methoxyisobutylisonitrile (^99m^Tc-MIBI) scintigraphy with the use of a double head VariCam (Elscint) gamma camera. Parallel hole, LEHR (low energy high resolution) collimators were used. Images were registered with a 128 × 128 matrix. A combined subtraction and two-phase acquisition protocol was used, with the initial part of the study being equivalent to the subtraction examination. Firstly, 60--74 MBq (1,6--2,0 mCi) of Na^99m^TcO~4~ was administered, and a thyroid image was obtained 10 minutes thereafter. Subsequently, 555÷740 MBq (15÷20 mCi) ^99m^Tc-MIBI was injected intravenously. The image of the neck was obtained after 20 minutes. Subtraction was performed by subtracting thyroid images from the ^99m^Tc-MIBI image. Further stages of the examination proceeded according to the standard two-phase study protocol. The ^99m^Tc-MIBI image obtained 20 minutes after administration of a radiopharmaceutical was regarded as "early" two-phase examination. The "late" neck acquisition was performed 120 minutes after ^99m^Tc-MIBI administration ([Fig. 1](#f0001){ref-type="fig"}). The detailed description of the study protocol and home-made computer program for analysis of parathyroid scintigraphy examinations were presented elsewhere^([@cit0006])^.

![An example of combined subtraction and two phase scintigraphy. Positive result: **A.** Na^99m^TcO~4~ thyroid scan; **B.** ^99m^Tc-MIBI scan 20 min after tracer injection; **C.** Subtraction scan; **D.** ^99m^Tc-MIBI scan 120 min after tracer injection](JoU-2017-0002-g001){#f0001}

Parathyroid scintigraphy was considered positive when the focus of tracer accumulation met the criteria of positive two-phase and/or subtraction study. Two-phase scintigraphy was considered positive when the focus of increased, abnormal accumulation of the radiopharmaceutical was found in the early image and its intensity increased in comparison to the surrounding tissues in the late image ([Fig. 2](#f0002){ref-type="fig"}). Subtraction scintigraphy was considered positive whenever the focus of tracer accumulation was found regardless of its intensity ([Fig. 3](#f0003){ref-type="fig"}).

![Two phase scintigraphy. Positive result. Extended retention of the radiopharmaceutical in the enlarged parathyroid](JoU-2017-0002-g002){#f0002}

![Subtraction scintigraphy. Positive result. A focus of increased radiopharmaceutical accumulation is visible as a result of subtraction](JoU-2017-0002-g003){#f0003}

Ultrasound {#sec2.2}
----------

The ultrasound examination of the neck was performed with the use of Aloka 680 ultrasound scanner equipped with a linear probe of 7.5 MHz, in 2D B mode presentation. The location of the parathyroid glands, their size and echostructure were assessed. Cross-sectional and longitudinal images of the anterior region of the neck were obtained. The bilateral assessment was performed in the region from the common carotid artery bifurcation to the midline and down to the sternum. An attempt to visualize the superior part of the mediastinum was performed.

Statistical analysis {#sec2.3}
--------------------

The usefulness of scintigraphy and US in detecting abnormal parathyroid glands was expressed as: (1) sensitivity -- the probability of obtaining a positive result in a patient with confirmed pathology, (2) specificity -- the probability of obtaining a negative result in a healthy patient. As both diagnostic tests were performed in eachpatient, McNemar's test was used to compare the proportions of correct results. A *p* value of \<0.05 was considered statistically significant. Calculations were carried out using the STATISTICA 10 package (StatSoft Inc., Tulsa, USA, 2011) and Confidence Interval Analysis (University of Southampton, Southampton, UK, 2009).

Results {#sec3}
=======

A total of 172 parathyroids glands were analyzed. Scintigraphy was true positive in 104, false positive in 8, true negative in 12 and false negative in 48 cases. The sensitivity and specificity of scintigraphy was 68% and 60%, respectively. Ultrasound results were true positive in 75, false positive in 3, true negative in 17 and false negative in 77 cases. The sensitivity of ultrasound was 49% and specificity 85%. Differences between scintigraphy and ultrasonography were statistically significant (*p* = 0.00001) for all analyzed parameters.

Both techniques allowed visualization of 76 parathyroid glands. Ultrasound revealed additional 19 glands that were not visible in scintigraphy. However, 76 parathyroid glands that were not visualized on ultrasound were found in scintigraphy. Having combined the results of scintigraphy and ultrasound, the sensitivity of 76% and specificity of 50% was obtained. Considering the ability to locate parathyroid glands in both techniques as a positive result, the sensitivity decreased to 37% and specificity rose to 95%.

Discussion {#sec4}
==========

In the published literature, the results of SC are usually compared with the results of US, rarely with CT or MR ([Tab. 2](#t0002){ref-type="table"}).

###### 

Comparison of sensitivity of various diagnostic methods in locating hyperfunctioning parathyroid gland

  Diagnostic method   Sensitivity                                Specificity
  ------------------- ------------------------------------------ -------------------
  US                  27%^([@cit0007])^                          65%^([@cit0007])^
  CT                  44 + 63%^([@cit0008])^ 13%^([@cit0007])^   39%^([@cit0007])^
  MR                  17%^([@cit0007])^                          65%^([@cit0007])^
  Scintigraphy        83%^([@cit0008])^ 57%^([@cit0007])^        85%^([@cit0007])^

Differences in their sensitivity and specificity in the published literature result from a number of factors affecting the results of the examination: studied group, equipment used, technique of examination and experience of a physician evaluating the results. Compared with the literature, the sensitivity of US and SC in the current study was moderate, which in our opinion is related to the mixed group of patients, including not only primary but also a high number of secondary and tertiary hyperparathyroidism. By contrast with US, CT or MRI, radionuclide techniques reflect the function of the assessed glands, not their anatomical structure. Functional imaging is especially important in ectopic parathyroid glands which appear approx. in 6--16% of patients^([@cit0009])^ and in cases of additional parathyroid glands (10 to 15%). Most commonly, the "errant" lower parathyroid gland is located in the thymus^([@cit0009],\ [@cit0010])^ and the upper gland behind the esophagus, in the upper mediastinum or within the thyroid gland parenchyma^([@cit0010]).^ The intraoperative location of all abnormal parathyroid glands can then cause considerable difficulties and may lead to ineffective operation.

Finding abnormal parathyroid glands is especially important in patients with a history of parathyroid operations and recurrent hyperparathyroidism, which occurs in approximately 1--4% of cases^([@cit0001]).^ The number of reoperated patients (first operation performed in other centers) in the analyzed group was 26. Changed anatomical conditions and presence of adhesions make it significantly harder to find the abnormal gland. These factors also increase the risk of recurrent laryngeal nerve injury.

Parathyroid scintigraphy is most commonly performed using MIBI (methoxyisobutylisonitrile radiopharmaceutical labeled with technetium-99m, which is a monovalent lipophilic cation, passively diffusing through the cell membrane. Coackley *et al*.^([@cit0011])^ was the first to notice accidental accumulation of ^99m^Tc-MIBI in the enlarged parathyroid glands. ^99m^Tc-MIBI is nowadays a reference radiopharmaceutical in the diagnosis of hyperparathyroidism. However the uniform protocol of parathyroid scintigraphy is still not established.

Parathyroid scintigraphy with ^99m^Tc-MIBI uses two main techniques: subtraction and two-phase scintigraphy.

Subtraction scintigraphy with the use of ^99m^Tc-MIBI involves comparing the ^99m^Tc-MIBI images with images obtained after administration of another radiopharmaceutical, which has affinity to the thyroid gland tissue, namely sodium iodide (Na^123^I, Na^131^I) or pertechnetate (Na^99m^TcO~4~).

The two-phase examination with ^99m^Tc-MIBI was introduced into routine practice by Taillefer *et al*., 1992^([@cit0012])^. It is based on differences in the pharmacokinetics of the radiopharmaceutical within the thyroid and parathyroid gland: initially it accumulates in both the thyroid and enlarged parathyroid glands. As time passes, the distribution of the radiopharmaceutical changes: intense accumulation of the tracer in enlarged parathyroid glands is still observed (the phenomenon of prolonged retention), while the accumulation in the thyroid gland and muscles gradually decreases. To this day, it is the most widely used technique in the imaging of parathyroid glands.

Own observations and published literature show that the two-phase technique can lead to false negative results: some of the affected parathyroid glands are characterized by rapid leaching of ^99m^Tc-MIBI^([@cit0013],\ [@cit0014])^. False positive results, in turn, may be caused by thyroid tumors, which may have enhanced and prolonged retention of the radiopharmaceutical. This problem is of particular importance in areas of endemic goiter^([@cit0008],\ [@cit0015],\ [@cit0016]).^ The presented results do not differ from those reported in the literature: Ishibashi *et al*.^([@cit0017])^, in a group of 26 patients with primary and secondary hyperparathyroidism, compared the results of tetrofosmin scintigraphy, US and MRI. The reported sensitivity of scintigraphy of 77.3% was superior to other imaging techniques: sensitivity of US was 45.5% and 68.2% for MRI. Yao *et al*.^([@cit0018])^, based on 37 patients with primary hyperparathyroidism, reported slightly lower sensitivity of scintigraphy (67%), similar results for US (44%) and only 36% for MRI.

In another study, Wakamatsu *et al*.^([@cit0019])^ obtained 51% sensitivity for US as well as 43% and 56% for MRI and scintigraphy, respectively. On the basis of these reports, we can say that the sensitivity of scintigraphy is significantly higher than that of other imaging techniques.

Different results were obtained by Lemmi *et al*.^([@cit0020])^ The sensitivity of US and CT in a group of 119 patients was 72% and 80%, respectively. Having combined the results of CT and ultrasound, the authors obtained a sensitivity of 87%.

On the other hand, Geatti *et al*.^([@cit0008])^, in 43 patients, compared the scintigraphic ^99m^Tc-MIBI two-phase and subtraction 201 Tl / ^99m^Tc examination with US and CT. The highest obtained sensitivity was 95% for ^99m^Tc-MIBI scintigraphy. The authors stressed better image quality, lower ^99m^Tc-MIBI cost than thallium and its easier availability. They pointed out that thanks to these factors ^99m^Tc-MIBI is a radiopharmaceutical of choice in the diagnosis of hyperparathyroidism.

In our material, the results of scintigraphy were comparable to those obtained by Yao *et al*.^([@cit0018])^ and the results of ultrasound were similar to the results of Wakamatsu *et al*.^([@cit0019])^. The most important fact was that, as in the literature, SC had higher sensitivity than US.

Having compared the results of ultrasound and scintigraphy in our own material, we obtained the highest sensitivity in the group of patients who had a positive result of at least one test; the sensitivity was 76% and specificity of 50%.

When analyzing the published data, it can be stated that ultrasound diagnosis of parathyroid glands encounters two main limitations: firstly, abnormal parathyroid glands are not visualized in many cases; secondly, normal anatomical structures or thyroid nodules are misinterpreted as enlarged parathyroids. The problem of misinterpretation of the nature of visualized structures largely depends on the experience of the reading physician. In the case of an abnormal ultrasound image or unusual location, ultrasound-guided biopsy or the use of Doppler technique enable correct diagnosis^([@cit0020],\ [@cit0021])^.

In the analyzed material, the specificity of ultrasound was greater than that of scintigraphy. Lower specificity of scintigraphy was mostly affected by false positive results due to thyroid gland abnormalities in more than 60% of patients. Ultrasound examination along with scintigraphy determined the nature of the visualized lesions and influenced specificity in a positive manner: in a group of patients where both studies were positive, it amounted to 95%, while the sensitivity was only 37%. The results showed that ultrasound should be performed along with scintigraphy, in order to improve specificity.

Conclusions {#sec5}
===========

Scintigraphy showed greater sensitivity than ultrasound in establishing the location of enlarged parathyroid glands; ultrasound was characterized by a higher specificity. The combined use of scintigraphy and ultrasonography allowed to obtain 95% specificity in the diagnosis of enlarged parathyroid glands. In the light of obtained results, scintigraphy and ultrasonography are complementary and should be used together.
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